Sobi's Pozdeutinurad Hits Phase 3 Gout Endpoint, 69.2% Reach Target
STOCKHOLM – October 29, 2026 -- Sobi's investigational gout drug pozdeutinurad (AR882) met the primary endpoint of the Phase 3 REDUCE-2 study, with 69.2% of patients on the 75 mg dose reaching serum urate (SU) below 6 mg/dL at month 6, against 8.1% on placebo. The company is presenting the late-breaking data at ACR Convergence 2026.
Both pozdeutinurad doses beat placebo on the primary endpoint at month 6
REDUCE-2 randomised 811 gout patients to pozdeutinurad 75 mg, pozdeutinurad 50 mg or placebo. In the 50 mg arm, 56.6% of patients achieved SU below 6 mg/dL at month 6. Both doses were significant versus placebo (p<0.0001).
Pozdeutinurad is a once-daily oral, highly selective URAT1 inhibitor. Sobi is developing it for uncontrolled gout, defined as SU above 6 mg/dL with persistent flares and/or tophi despite oral urate-lowering therapy.